A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Pfizer CT.gov Call Center
Pfizer
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
486 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Patricia Ritchie Centre for Cancer Care and Research Mater Hospital Sydney
North Sydney, New South Wales, Australia
- the Crown Princess Mary Cancer Centre, Westmead Hospital
Westmead, New South Wales, Australia
- Austin Health
Heidelberg, Victoria, Australia
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- the Royal Melbourne Hospital
Parkville, Victoria, Australia
- Epic Pharmacy Hollywood
Nedlands, Western Australia, Australia
- Hollywood Private Hospital
Nedlands, Western Australia, Australia
- Starcevich Day Clinic, Hollywood Private Hospital
Nedlands, Western Australia, Australia
- Breast Cancer Research Centre - Wa
Nedlands, Australia
- Universitatsklinik Innsbruck Fur Gynakologie Und Geburtshilfe Brustgesundheitzentrum
Innsbruck, Austria
- Ct/mrifacility:diagnosezentrum Urania
Vienna, Austria
- Klinik Ottakring.
Vienna, Austria
- Wilhelminen Krebsforschung Gmbh
Vienna, Austria
- Institut Jules Bordet
Anderlecht, Bruxelles-capitale, Région de, Belgium
- Clinical Trails Conduct Unit(ctcu) Institut Jules Bordet
Brussels, Belgium
- Ghdc
Charleroi, Belgium
- University Hospital Antwerp
Edegem, Belgium
- Az Groeninge
Kortrijk, Belgium
- Uz Leuven
Leuven, Belgium
- Chu de Liege
Liège, Belgium
- Chu Ucl Site Sainte Elisabeth
Namur, Belgium
- Cross Cancer Institute
Edmonton, Alberta, Canada
- London Regional Cancer Program, London Health Sciences Centre
London, Ontario, Canada
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Centre Hospitalier de L'Universite de Motreal (chum)
Montreal, Quebec, Canada
- Chu de Québec-Université Laval, St-Sacrement Hospital
Québec, Canada
- Maternal and Child Health Hospital of Guangdong Province
Guangzhou, Guangdong, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- Hunan Cancer Hospital.
Changsha, Hu'nan, China
- Hubei Cancer Hospital
Wuhan, Hubei, China
- Renmin Hospital of Wuhan University
Wuhan, Hubei, China
- Nanjing Drum Tower Hospital , the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
- Xuzhou Central Hospital
Xuzhou, Jiangsu, China
- Nanchang Third Hospital
Nanchang, Jiangxi, China
- Jilin Cancer Hospital
Changchun, Jilin, China
- Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
- the First Affiliated Hospital of Xi'An Jiaotong University
Xi’an, Shanxi, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Oct 2019
- Primary completion
- 29 Jun 2023
- Completion
- 10 Mar 2029
- Last update posted
- 30 Mar 2026
- Registered enrollment
- 466
- Registry id
- NCT03975647
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.